- Home
- HYFM vs BLRX Comparison
HYFM vs BLRX Comparison
Compare HYFM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- BLRX
- Stock Information
- Founded
- HYFM 1977
- BLRX 2003
- Country
- HYFM United States
- BLRX Israel
- Employees
- HYFM N/A
- BLRX N/A
- Industry
- HYFM Industrial Machinery/Components
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- BLRX Health Care
- Exchange
- HYFM Nasdaq
- BLRX Nasdaq
- Market Cap
- HYFM 17.3M
- BLRX 17.0M
- IPO Year
- HYFM 2020
- BLRX 2011
- Fundamental
- Price
- HYFM $4.34
- BLRX $3.87
- Analyst Decision
- HYFM Hold
- BLRX Strong Buy
- Analyst Count
- HYFM 2
- BLRX 2
- Target Price
- HYFM $7.00
- BLRX $19.00
- AVG Volume (30 Days)
- HYFM 11.2K
- BLRX 35.3K
- Earning Date
- HYFM 08-12-2025
- BLRX 08-14-2025
- Dividend Yield
- HYFM N/A
- BLRX N/A
- EPS Growth
- HYFM N/A
- BLRX N/A
- EPS
- HYFM N/A
- BLRX N/A
- Revenue
- HYFM $176,650,000.00
- BLRX $22,340,000.00
- Revenue This Year
- HYFM $5.45
- BLRX N/A
- Revenue Next Year
- HYFM $5.33
- BLRX N/A
- P/E Ratio
- HYFM N/A
- BLRX N/A
- Revenue Growth
- HYFM N/A
- BLRX 91.68
- 52 Week Low
- HYFM $1.50
- BLRX $2.30
- 52 Week High
- HYFM $8.55
- BLRX $35.02
- Technical
- Relative Strength Index (RSI)
- HYFM 56.32
- BLRX 36.06
- Support Level
- HYFM $3.88
- BLRX $4.47
- Resistance Level
- HYFM $4.73
- BLRX $4.32
- Average True Range (ATR)
- HYFM 0.34
- BLRX 0.27
- MACD
- HYFM -0.01
- BLRX -0.08
- Stochastic Oscillator
- HYFM 60.20
- BLRX 15.38
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.